GSK plc (NYSE:GSK) Shares Acquired by Choate Investment Advisors

Choate Investment Advisors lifted its stake in GSK plc (NYSE:GSK) by 6.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,177 shares of the pharmaceutical company’s stock after acquiring an additional 1,655 shares during the quarter. Choate Investment Advisors’ holdings in GSK were worth $953,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in GSK. Dorsey & Whitney Trust CO LLC grew its holdings in shares of GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after purchasing an additional 278 shares during the last quarter. Sunbelt Securities Inc. grew its stake in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. Rehmann Capital Advisory Group increased its position in GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares during the period. GC Wealth Management RIA LLC lifted its stake in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after buying an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC grew its position in shares of GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after acquiring an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.8 %

Shares of GSK stock opened at $39.54 on Monday. The firm has a market cap of $81.94 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The company’s 50-day simple moving average is $36.05 and its 200-day simple moving average is $37.01. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 3.98%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 98.74%.

Analyst Ratings Changes

GSK has been the subject of several research reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.